AstraZeneca's (AZN) LOKELMA Granted Fast Track Designation in the US to Reduce Cardiovascular Outcomes in Patients on Chronic Hemodialysis With Hyperkalemia

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. IBM
6. MU
7. FDX
8. BLZE
9. NKE
10. PRIM

Go back to AstraZeneca's (AZN) LOKELMA Granted Fast Track Designation in the US to Reduce Cardiovascular Outcomes in Patients on Chronic Hemodialysis With Hyperkalemia

New Data Phase 3 Data Confirms Robust Efficacy and Long-Term Prevention Effects of AstraZeneca (AZN) AZD7442

November 18, 2021 5:10 AM EST

AstraZeneca (NASDAQ: AZN) reports new data from the AZD7442 COVID-19 PROVENT prevention and TACKLE outpatient treatment Phase III trials, with both demonstrating robust efficacy from a one-time intramuscular (IM) dose of the long-acting antibody (LAAB) combination.

In an analysis of the ongoing PROVENT trial evaluating a median six months of participant follow-up, one 300mg IM dose of AZD7442 reduced the risk of developing symptomatic COVID-19 compared to placebo by 83%.

About 2% of the global population is considered at increased risk of an inadequate response to a COVID-19 vaccine.1 This includes people with blood... More